Future Oncology

Papers
(The H4-Index of Future Oncology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up117
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes85
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma77
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study62
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis49
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer49
Is Obesity a Risk Factor in Cancer Patients with COVID-19?44
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression44
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma43
Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma43
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?41
Sex bias phenomenon in oral cancer: an insight41
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma40
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges39
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil39
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?39
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer38
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice38
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)38
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe36
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study36
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study36
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)36
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis35
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges35
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer34
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression33
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib31
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study30
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon30
0.13270092010498